{"protocolSection":{"identificationModule":{"nctId":"NCT06482307","orgStudyIdInfo":{"id":"19310"},"organization":{"fullName":"University Medical Center Groningen","class":"OTHER"},"briefTitle":"Molecular Imaging of DNA Damage Response by [18F]-Olaparib PET","officialTitle":"Molecular Imaging of DNA Damage Response by [18F]-Olaparib PET","acronym":"[18F]-olaparib"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-10","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2025-10","type":"ESTIMATED"},"completionDateStruct":{"date":"2025-10","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-25","studyFirstSubmitQcDate":"2024-06-25","studyFirstPostDateStruct":{"date":"2024-07-01","type":"ESTIMATED"},"lastUpdateSubmitDate":"2024-06-25","lastUpdatePostDateStruct":{"date":"2024-07-01","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"University Medical Center Groningen","class":"OTHER"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This is a single-centre, non-randomized, two-stage design, proof-of-concept study evaluating the radiolabelled PARP inhibitor \\[18F\\]-olaparib als potential tracer for imaging of tumour PARP expression by PET."},"conditionsModule":{"conditions":["Head and Neck Squamous Cell Carcinoma (HNSCC)"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"SINGLE_GROUP","interventionModelDescription":"patients with HNSCC","primaryPurpose":"DIAGNOSTIC","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":10,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Stage I","type":"EXPERIMENTAL","description":"Five patients with HNSCC will undergo a dynamic \\[18F\\]-olaparib PET during 30 min, followed by a static whole body PET scans at 120 min post-injection of \\[18F\\]-olaparib.","interventionNames":["Diagnostic Test: [18F]-olaparib PET scan"]},{"label":"Stage II","type":"EXPERIMENTAL","description":"After determination of the most optimal time point for imaging, five patients with HNSCC scheduled for chemoradiotherapy will undergo serial \\[18F\\]-olaparib PET at baseline (i.e. prior to treatment initiation) and a second scan during the first week of chemoradiotherapy. Patients in stage II will undergo a study biopsy in the first week of chemoradiotherapy to evaluate changes in PARP protein expression.","interventionNames":["Diagnostic Test: [18F]-olaparib PET scan"]}],"interventions":[{"type":"DIAGNOSTIC_TEST","name":"[18F]-olaparib PET scan","description":"The IMP investigated is \\[18F\\]Olaparib, a radiolabelled PARP inhibitor suitable for PET imaging.","armGroupLabels":["Stage I","Stage II"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Dosimetry assessment","description":"Assess dosimetry, most optimal time point for imaging (Stage I), and safety of \\[18F\\]olaparib PET (Stage I + II)","timeFrame":"6-12 months"},{"measure":"Correlation between tumour uptake and expression","description":"Determine the correlation between tumour \\[18F\\]-olaparib uptake and tumour PARP-1 expression levels on tumour biopsy (Stage I + II).","timeFrame":"12-18 months"}],"secondaryOutcomes":[{"measure":"Evaluation of changes in tumour uptake","description":"Evaluate changes in tumour \\[18F\\]-olaparib uptake, as a read-out of DNA damage, during treatment with platinum-based chemoradio-therapy, and its correlation with changes in PARP protein expression (Stage II).","timeFrame":"12-18 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Patients \\>18y, with biopsy-proven HPV-negative HNSCC, or patients \\>40y with HPV-positive HNSCC and high-risk features (i.e. \\> 10 smoke packs/year AND ≥N2b)\n2. Treatment with chemoradiotherapy using platinum-based chemotherapy is anticipated\n3. Recent archival tumour tissue (\\<8 weeks prior to inclusion) should be available with suffi-cient residual material for determination of tumour PARP1 levels\n4. Presence of a tumour lesion ≥10 mm in diameter\n5. ECOG performance status 0-2\n6. Negative pregnancy test in women with childbearing potential\n7. Life expectancy \\>3 months\n8. Signed written informed consent and able to comply with the protocol\n9. For stage II only: re-biopsy should be deemed feasible by the investigators (assessed by head-and-neck surgeon)\n\nExclusion Criteria:\n\n1. Recent treatment with PARP inhibitors or other investigational therapies \\<30 days.\n2. Presence of significant co-morbidities that make participation in the study undesirable according to the treating physician.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Michel van Kruchten, MD, PhD","role":"CONTACT","phone":"+31 50 361 2821","email":"m.van.kruchten@umcg.nl"}],"overallOfficials":[{"name":"Michel van Kruchten, MD, PhD","affiliation":"University Medical Center Groningen","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"University Medical Center Groningen","city":"Groningen","zip":"9713 GZ","country":"Netherlands","contacts":[{"name":"Michel van Kruchten, MD, PhD","role":"CONTACT","phone":"+31 50 361 2821","email":"m.van.kruchten@umcg.nl"},{"name":"Michel van Kruchten, MD, PhD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":53.21917,"lon":6.56667}}]},"ipdSharingStatementModule":{"ipdSharing":"UNDECIDED"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000077195","term":"Squamous Cell Carcinoma of Head and Neck"}],"ancestors":[{"id":"D000002294","term":"Carcinoma, Squamous Cell"},{"id":"D000002277","term":"Carcinoma"},{"id":"D000009375","term":"Neoplasms, Glandular and Epithelial"},{"id":"D000009370","term":"Neoplasms by Histologic Type"},{"id":"D000009369","term":"Neoplasms"},{"id":"D000006258","term":"Head and Neck Neoplasms"},{"id":"D000009371","term":"Neoplasms by Site"}],"browseLeaves":[{"id":"M5534","name":"Carcinoma","relevance":"LOW"},{"id":"M5550","name":"Carcinoma, Squamous Cell","relevance":"LOW"},{"id":"M1689","name":"Squamous Cell Carcinoma of Head and Neck","asFound":"Head and Neck Squamous Cell Carcinoma","relevance":"HIGH"},{"id":"M12320","name":"Neoplasms, Glandular and Epithelial","relevance":"LOW"},{"id":"M12315","name":"Neoplasms by Histologic Type","relevance":"LOW"},{"id":"M9348","name":"Head and Neck Neoplasms","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"All","name":"All Conditions"}]},"interventionBrowseModule":{"meshes":[{"id":"C000531550","term":"Olaparib"}],"ancestors":[{"id":"D000067856","term":"Poly(ADP-ribose) Polymerase Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000000970","term":"Antineoplastic Agents"}],"browseLeaves":[{"id":"M233003","name":"Olaparib","asFound":"Daily dose","relevance":"HIGH"},{"id":"M205","name":"Poly(ADP-ribose) Polymerase Inhibitors","relevance":"LOW"},{"id":"M7951","name":"Enzyme Inhibitors","relevance":"LOW"}],"browseBranches":[{"abbrev":"ANeo","name":"Antineoplastic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}